News
IOBT
0.7009
+0.60%
0.0042
Weekly Report: what happened at IOBT last week (1201-1205)?
Weekly Report · 5h ago
Weekly Report: what happened at IOBT last week (1124-1128)?
Weekly Report · 12/01 10:14
Thanksgiving: Top 10 Most Innovative BioPharma Drugs In Phase 3
Seeking Alpha · 11/27 12:20
IO Biotech Announces Participation in Upcoming December Investor Conferences
Barchart · 11/26 09:46
Weekly Report: what happened at IOBT last week (1117-1121)?
Weekly Report · 11/24 10:19
IO Biotech Announces Resignation of Chief Accounting Officer
TipRanks · 11/21 21:56
IO Biotech Appoints CFO Amy Sullivan as Principal Accounting Officer
Reuters · 11/21 21:44
IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's Why
NASDAQ · 11/19 17:00
Piper Sandler Sticks to Its Buy Rating for IO Biotech (IOBT)
TipRanks · 11/19 11:55
IO Biotech’s Q3 2025: Progress in Cancer Vaccine Trials
TipRanks · 11/19 04:03
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 11/18 17:06
IO Biotech Presents at Jefferies Global Healthcare Conference
TipRanks · 11/18 11:58
Weekly Report: what happened at IOBT last week (1110-1114)?
Weekly Report · 11/17 10:19
IO Biotech’s Hold Rating Amid Financial and Regulatory Uncertainty
TipRanks · 11/15 17:15
Analysts Are Neutral on Top Healthcare Stocks: Anavex Life Sciences (AVXL), IO Biotech (IOBT)
TipRanks · 11/14 17:50
IO Biotech GAAP EPS of -$0.13 beats by $0.25
Seeking Alpha · 11/14 13:31
IO Biotech reports $8.4 mln Q3 net loss
Reuters · 11/14 13:13
IO Biotech Q3 EPS $(0.13) Beats $(0.34) Estimate
Benzinga · 11/14 13:11
IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights
Barchart · 11/14 07:05
Weekly Report: what happened at IOBT last week (1103-1107)?
Weekly Report · 11/10 10:16
More
Webull provides a variety of real-time IOBT stock news. You can receive the latest news about Io Biotech, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About IOBT
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.